Tesamorelin (Egrifta SV)

What is Tesamorelin (Egrifta SV)?

Tesamorelin is an FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) — the signal your brain naturally sends to trigger growth hormone release. It is sold under the brand name Egrifta SV and is the only FDA-approved peptide specifically for reducing excess visceral fat in HIV-positive adults experiencing lipodystrophy caused by antiretroviral drugs. Unlike direct growth hormone injections, tesamorelin works by nudging your own pituitary gland to produce growth hormone in a more natural, pulsatile rhythm.

How does Tesamorelin (Egrifta SV) work?

When injected, tesamorelin binds to GHRH receptors in the pituitary gland, triggering the release of your body's own growth hormone in natural pulses — much like the signal your hypothalamus would normally send. This rise in growth hormone then stimulates IGF-1 (insulin-like growth factor 1), which promotes fat breakdown, particularly in the visceral (deep abdominal) fat compartment. Because it works through your own pituitary rather than flooding the body with exogenous GH, the hormonal pattern stays closer to normal physiology.

What forms does Tesamorelin (Egrifta SV) come in?

Available exclusively as a lyophilized (freeze-dried) powder for reconstitution and subcutaneous injection. Egrifta SV (the current formulation) requires less diluent volume than the original Egrifta, making self-injection more convenient. No oral or topical form exists because peptides are broken down in the digestive tract before absorption.

Where it comes from:

Tesamorelin was developed by Theratechnologies (Canada) and received FDA approval in 2010 specifically for HIV-associated lipodystrophy — a condition where antiretroviral therapy causes abnormal fat redistribution, particularly deep belly fat accumulation. The Egrifta SV reformulation was approved in 2019. It remains the only GHRH analogue with full FDA approval for a specific fat-reduction indication.

What does Tesamorelin (Egrifta SV) help with?

• HIV-associated belly fat (lipodystrophy): Many HIV-positive people on long-term antiretroviral therapy develop a hard, round accumulation of deep belly fat that diet and exercise barely touch. Tesamorelin is the only FDA-approved treatment for this specific condition, and clinical trials showed it reduced visceral fat area by roughly 15–18% compared to placebo over 6 months.
• Excess visceral (deep abdominal) fat: Visceral fat — the fat that wraps around your organs rather than sitting under the skin — is strongly linked to heart disease, insulin resistance, and inflammation. Tesamorelin specifically targets this depot by restoring growth hormone signaling, which preferentially mobilizes visceral fat for energy.
• Body composition and lean mass: Beyond fat loss, tesamorelin helps preserve or modestly increase lean body mass. Users in clinical studies experienced improvements in the waist-to-hip ratio and overall body composition, even without major changes to diet or exercise.
• Elevated triglycerides in HIV patients: Visceral fat and impaired GH signaling both drive up triglyceride levels. Clinical trials found that tesamorelin produced modest but meaningful reductions in triglycerides alongside its fat-reduction effects, which matters for heart health in this population.
• Cognitive function in older adults: Emerging research suggests tesamorelin may support memory and processing speed in older adults, potentially because growth hormone and IGF-1 play important roles in brain health. This is an active area of investigation and not yet a mainstream clinical application.
• Non-alcoholic fatty liver disease (NAFLD): Preliminary research indicates that tesamorelin may reduce liver fat in people with NAFLD, particularly those who also have visceral obesity. Studies are still early but the mechanism makes biological sense — lowering visceral fat reduces the fat load delivered to the liver.
• Growth hormone deficiency (off-label): Some clinicians use tesamorelin off-label to address age-related decline in growth hormone, sometimes called somatopause. It stimulates the pituitary rather than replacing GH directly, which some practitioners consider a more physiological approach.
• Metabolic syndrome features: Because tesamorelin improves visceral fat, triglycerides, and body composition simultaneously, it addresses several features of metabolic syndrome at once. Research is ongoing to clarify how meaningful these benefits are beyond the HIV-lipodystrophy context.

What can Tesamorelin (Egrifta SV) help prevent?

• Progression of visceral fat accumulation in HIV-related lipodystrophy
• Worsening dyslipidemia (elevated triglycerides) associated with antiretroviral therapy

Which foods are rich in Tesamorelin (Egrifta SV)?

Tesamorelin is a synthetic peptide that cannot be obtained from food — it must be injected. However, you can support healthy growth hormone signaling naturally through diet. Foods that help: lean protein at each meal (chicken, fish, eggs, Greek yogurt) supports GH pulse amplitude; cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) help manage estrogen and visceral fat; healthy fats from avocado, olive oil, and fatty fish reduce the systemic inflammation that blunts GH release; and avoiding high-sugar, high-refined-carb meals is especially important because blood sugar spikes acutely suppress GH secretion. Intermittent fasting or simply not eating within 2–3 hours of sleep can meaningfully boost natural GH pulses overnight.

What are the side effects of Tesamorelin (Egrifta SV)?

• Injection site reactions (redness, itching, swelling): most common complaint
• Joint pain or stiffness (arthralgia)
• Fluid retention / mild swelling in the limbs
• Numbness or tingling (peripheral neuropathy-like symptoms)
• Elevated blood sugar or worsening insulin resistance
• Muscle pain (myalgia)
• Nausea
• Elevated IGF-1 levels (requires monitoring)
• Rare: carpal tunnel syndrome symptoms
• Rare: hypersensitivity or allergic reaction

Good to know:

Tesamorelin is generally considered safe at its approved dose when used under medical supervision. Most side effects are mild and manageable. Because it raises growth hormone and IGF-1, there are important contraindications: it should not be used in people with active cancer, during pregnancy, or with hypopituitarism from structural lesions.

How much Tesamorelin (Egrifta SV) should you take?

• Recommended daily: 2 mg subcutaneous injection once daily (FDA-approved dose for HIV-associated lipodystrophy). Off-label longevity use often explored at 1–2 mg/day under physician supervision.
• Best time of day: Evening injection before bed is often preferred to align with the body's natural overnight growth hormone pulse, though morning dosing is also used clinically. Consistency matters more than exact timing.
• With or without food: Inject on an empty stomach or at least 2 hours after a meal when possible. High blood sugar at the time of injection blunts the pituitary GH response.
• Time to effect: IGF-1 levels rise within days; measurable visceral fat reduction typically requires 3–6 months of consistent daily use.
• How long to take it: FDA approval supports ongoing use for the lipodystrophy indication as long as benefit continues. Visceral fat typically returns within 6–12 weeks of stopping. Some off-label longevity protocols use 5 days on / 2 days off cycles to reduce tolerance. Always use under physician supervision with periodic IGF-1 monitoring.